UK markets close in 7 hours
  • FTSE 100

    7,187.87
    +80.10 (+1.13%)
     
  • FTSE 250

    18,765.79
    +171.31 (+0.92%)
     
  • AIM

    874.04
    -0.55 (-0.06%)
     
  • GBP/EUR

    1.1731
    +0.0031 (+0.27%)
     
  • GBP/USD

    1.1974
    +0.0052 (+0.44%)
     
  • BTC-GBP

    17,047.30
    +84.17 (+0.50%)
     
  • CMC Crypto 200

    444.05
    +8.53 (+1.96%)
     
  • S&P 500

    3,845.08
    +13.69 (+0.36%)
     
  • DOW

    31,037.68
    +69.86 (+0.23%)
     
  • CRUDE OIL

    98.88
    +0.35 (+0.36%)
     
  • GOLD FUTURES

    1,741.00
    +4.50 (+0.26%)
     
  • NIKKEI 225

    26,490.53
    +382.88 (+1.47%)
     
  • HANG SENG

    21,643.58
    +56.92 (+0.26%)
     
  • DAX

    12,804.00
    +209.48 (+1.66%)
     
  • CAC 40

    6,004.14
    +91.76 (+1.55%)
     

BUZZ-GlaxoSmithKline Plc: Shingles vaccine could be better than Merck's - Cowen

** Drugmaker's U.S.-listed shares up 1.3 pct at $46.75 premarket, London-listed up nearly 2 pct

** Cowen & Co analysts say GSK's vaccine to treat shingles may be more effective than Merck (LSE: 0O14.L - news) 's

** Glaxo's vaccine HZ/su should be well positioned to capture market share from Merck's Zostavax if final data from a late-stage study shows HZ/su has better efficacy while treating older patients, Cowen says

** Final data from late-stage study expected in H1 2015

** Merck sold $765 mln worth Zostavax worldwide in 2014

** Barclays (LSE: BARC.L - news) raised its price target on European drugmakers, including GSK's London-listed stock

** GSK up nearly 2 pct on the LSE

** Through Monday, the U.S. stock had gained 10 pct since Dec. 18, when GSK reported early data from the late-stage study

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting